Together, these outcomes suggest that formononetin shows an anticarcinogenic effect on bladder cancer based on in vitro investigations, which can be caused by the miR-21-initiated directive of the PTEN/Akt cascade [39]. Here, AKT1 is linked to urinary bladder cancer.